MEGA SOCRA CCRP EXAM CONTENT
STUDY GUIDE (NEWEST ACTUAL EXAM
QUESTIONS BANK / 750+ COMPLETE
ACCURATE QUIZZES WITH DETAILED
VERIFIED ANSWERS EXAM 2025 LATEST
NEWEST UPDATE WITH ACTUAL
QUESTIONS AND DETAILED VERIFIED
ANSWERS WITH RATIONALES (100%
CORRECT) //BRAND NEW!! /ALREADY
GRADED A+ WITH GUARANTEED
SUCCESS AFTER DOWNLOAD (ALL YOU
NEED TO PASS YOUR EXAMS
. Which of the following options describes the term "severe" in regards to ICH?
The Intensity of a specific event
Subject 3826 had to stay in the hospital for three extra days when his legs started swelling
after participation in a cardiac drug study. Swelling of the legs was listed in the Investigator's
Brochure as a possible side effect. Which of the following options best describes this
situation?
Serious Adverse Drug Reaction
A subject in your diabetes research study developed colon cancer, which the Investigator has
determined to be unrelated to the study. The subject is currently asymptomatic. This will be
, considered a serious adverse event because it is life threatening. Is this a true or false
statement?
FALSE
In pre-market approval studies, all noxious and unintended responses to a medicinal product,
even possibly related to any dose, should be considered which of the following options?
Adverse Drug Reaction
A subject has a suspected serious adverse drug reaction with the outcome of death. Per the
ICH E2A guideline, which are items that should be submitted to the Sponsor?
1. A de-identified autopsy report, if available
2. Cause of death, and a comment on its possible relationship to the suspected drug reaction
Two weeks after starting an investigational therapy, a subject is rushed to the hospital after
experiencing a heart attack. The subject is currently being treated in the Intensive Care Unit
(ICU). The ICU doctor has noticed that the subject was enrolled in the trial and has contacted
the trial Principal Investigator. Heart attack is not described in the Investigator's Brochure.
What actions must be taken by the Principal Investigator?
1. Report to the Sponsor per the protocol timelines for serious, unexpected events.
2. Report to the IRB/IEC per their event reporting requirements for serious, unexpected
events.
What is the timeframe for "expedited" reporting of serious, fatal or life-threatening,
unexpected adverse drug reactions to regulatory authorities?
As soon as possible, but no later than seven calendar days after first knowledge of the event
Adverse Drug Reaction (ADR) Example
Your third subject in a Phase III drug trial calls to report that she has developed a rash on her
chest 12 hours after taking her second dose of the investigational study drug. She states that it
itches and is slightly uncomfortable. She tells you that she has never had a rash and this is
totally unexpected. You know from the Investigator Drug Brochure that only 12% of the
patients get a rash from this drug. Which of the following options best describes this
situation?
What is the purpose of the IRB/IEC?
Safeguard the rights, safety, and well-being of all trial subjects
Who is responsible for designing the clinical trial protocol?
Sponsor
, Informed Consent Process
The process by which a subject voluntarily confirms his or her willingness to participate in a
clinical trial is best described as which of the following options?
The Monitor
Who is ultimately responsible for Source Data Verification or SDV?
A. At least five members
B. At least one member whose primary interest is non-scientific
C. At least one member who is independent from the Institution/trial site
The IRB/IEC should consist of a reasonable number of members, who collectively have the
qualifications and experience to review and evaluate the science, medical aspects, and ethics
of the proposed trial. It is recommended that the IRB/IEC should include which of the
following options?
Which of the following is NOT one of the required elements of an informed consent form?
A listing of all site personnel who will be involved in the research
Name 3 of several required elements of an informed consent form
1. The purpose of the research
2. A description of benefits that may be reasonably expected from the research
3. A contact person for questions about the research
According to ICH E6, who must sign the Informed Consent Form or ICF?
The person who conducted the informed consent discussion
The subject or the subject's legally acceptable representative
As per ICH E6 GCP, which groups of potential subjects could be defined as "vulnerable
subjects"?
Members of the armed forces
Patients with incurable diseases
Persons in nursing homes
As per ICH E6 GCP, patients with heart conditions alone are defined as "vulnerable
subjects"?
False
5
, The minimum number of IRB members
Subjects cannot be enrolled until IRB/IEC approval has been obtained
In a non-emergency situation, under which of the following conditions, if any, may subjects
be enrolled into a study prior to IRB/IEC approval?
The Sponsor
The responsibility for ensuring that the investigator understands a clinical trial lies with:
A subject has been enrolled on a study and was randomized to the non-treatment arm. The
protocol outlines study procedures for all subjects to be performed within one week of
enrollment. Which of the following statements about this case is correct?
This subject should undergo all study procedures as outlined in the protocol
A significant risk device is defined as an investigational device that is:
a. Intended as an implant and presents a potential for serious risk to the health, safety, or
welfare of a subject.
b. Purported or represented to be for a use in supporting or sustaining human life and presents
a potential risk to the health, safety, or welfare of a subject.
c. For a use of substantial importance in diagnosing, curing, mitigating, or treating disease, or
otherwise preventing impairment of human health and presents a potential for serious risk to
the health, safety, or welfare of a subject.
With respect to IRB/IEC membership, both the FDA and the ICH require that
At least one member's primary area of interest is in a nonscientific area
The rights, safety, and well-being of human subjects are protected
A purpose of monitoring clinical trials is to verify that:
Which of the following is the proper way to make a correction to a CRF?
STUDY GUIDE (NEWEST ACTUAL EXAM
QUESTIONS BANK / 750+ COMPLETE
ACCURATE QUIZZES WITH DETAILED
VERIFIED ANSWERS EXAM 2025 LATEST
NEWEST UPDATE WITH ACTUAL
QUESTIONS AND DETAILED VERIFIED
ANSWERS WITH RATIONALES (100%
CORRECT) //BRAND NEW!! /ALREADY
GRADED A+ WITH GUARANTEED
SUCCESS AFTER DOWNLOAD (ALL YOU
NEED TO PASS YOUR EXAMS
. Which of the following options describes the term "severe" in regards to ICH?
The Intensity of a specific event
Subject 3826 had to stay in the hospital for three extra days when his legs started swelling
after participation in a cardiac drug study. Swelling of the legs was listed in the Investigator's
Brochure as a possible side effect. Which of the following options best describes this
situation?
Serious Adverse Drug Reaction
A subject in your diabetes research study developed colon cancer, which the Investigator has
determined to be unrelated to the study. The subject is currently asymptomatic. This will be
, considered a serious adverse event because it is life threatening. Is this a true or false
statement?
FALSE
In pre-market approval studies, all noxious and unintended responses to a medicinal product,
even possibly related to any dose, should be considered which of the following options?
Adverse Drug Reaction
A subject has a suspected serious adverse drug reaction with the outcome of death. Per the
ICH E2A guideline, which are items that should be submitted to the Sponsor?
1. A de-identified autopsy report, if available
2. Cause of death, and a comment on its possible relationship to the suspected drug reaction
Two weeks after starting an investigational therapy, a subject is rushed to the hospital after
experiencing a heart attack. The subject is currently being treated in the Intensive Care Unit
(ICU). The ICU doctor has noticed that the subject was enrolled in the trial and has contacted
the trial Principal Investigator. Heart attack is not described in the Investigator's Brochure.
What actions must be taken by the Principal Investigator?
1. Report to the Sponsor per the protocol timelines for serious, unexpected events.
2. Report to the IRB/IEC per their event reporting requirements for serious, unexpected
events.
What is the timeframe for "expedited" reporting of serious, fatal or life-threatening,
unexpected adverse drug reactions to regulatory authorities?
As soon as possible, but no later than seven calendar days after first knowledge of the event
Adverse Drug Reaction (ADR) Example
Your third subject in a Phase III drug trial calls to report that she has developed a rash on her
chest 12 hours after taking her second dose of the investigational study drug. She states that it
itches and is slightly uncomfortable. She tells you that she has never had a rash and this is
totally unexpected. You know from the Investigator Drug Brochure that only 12% of the
patients get a rash from this drug. Which of the following options best describes this
situation?
What is the purpose of the IRB/IEC?
Safeguard the rights, safety, and well-being of all trial subjects
Who is responsible for designing the clinical trial protocol?
Sponsor
, Informed Consent Process
The process by which a subject voluntarily confirms his or her willingness to participate in a
clinical trial is best described as which of the following options?
The Monitor
Who is ultimately responsible for Source Data Verification or SDV?
A. At least five members
B. At least one member whose primary interest is non-scientific
C. At least one member who is independent from the Institution/trial site
The IRB/IEC should consist of a reasonable number of members, who collectively have the
qualifications and experience to review and evaluate the science, medical aspects, and ethics
of the proposed trial. It is recommended that the IRB/IEC should include which of the
following options?
Which of the following is NOT one of the required elements of an informed consent form?
A listing of all site personnel who will be involved in the research
Name 3 of several required elements of an informed consent form
1. The purpose of the research
2. A description of benefits that may be reasonably expected from the research
3. A contact person for questions about the research
According to ICH E6, who must sign the Informed Consent Form or ICF?
The person who conducted the informed consent discussion
The subject or the subject's legally acceptable representative
As per ICH E6 GCP, which groups of potential subjects could be defined as "vulnerable
subjects"?
Members of the armed forces
Patients with incurable diseases
Persons in nursing homes
As per ICH E6 GCP, patients with heart conditions alone are defined as "vulnerable
subjects"?
False
5
, The minimum number of IRB members
Subjects cannot be enrolled until IRB/IEC approval has been obtained
In a non-emergency situation, under which of the following conditions, if any, may subjects
be enrolled into a study prior to IRB/IEC approval?
The Sponsor
The responsibility for ensuring that the investigator understands a clinical trial lies with:
A subject has been enrolled on a study and was randomized to the non-treatment arm. The
protocol outlines study procedures for all subjects to be performed within one week of
enrollment. Which of the following statements about this case is correct?
This subject should undergo all study procedures as outlined in the protocol
A significant risk device is defined as an investigational device that is:
a. Intended as an implant and presents a potential for serious risk to the health, safety, or
welfare of a subject.
b. Purported or represented to be for a use in supporting or sustaining human life and presents
a potential risk to the health, safety, or welfare of a subject.
c. For a use of substantial importance in diagnosing, curing, mitigating, or treating disease, or
otherwise preventing impairment of human health and presents a potential for serious risk to
the health, safety, or welfare of a subject.
With respect to IRB/IEC membership, both the FDA and the ICH require that
At least one member's primary area of interest is in a nonscientific area
The rights, safety, and well-being of human subjects are protected
A purpose of monitoring clinical trials is to verify that:
Which of the following is the proper way to make a correction to a CRF?
